<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639819</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160096H</org_study_id>
    <nct_id>NCT02639819</nct_id>
  </id_info>
  <brief_title>Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study</brief_title>
  <acronym>MANICHAN-PILOT</acronym>
  <official_title>A Pilot Study of Ultra-Early Intravenous ɛ-Aminocaproic Acid in Spontanteous Intracerebral Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is single-arm, open-label, safety and feasibility pilot study of ɛ-aminocaproic acid in
      ICH patients.

      Consecutive ICH volume with hematoma volume less than 30 mL by ABC/2 method presenting within
      3 hours of symptom onset, meeting all inclusion criteria, and without exclusions will be
      consented and enrolled. Subjects will receive 5 grams of intravenous ɛ-aminocaproic acid over
      1 hour, followed by the same at 1 mg/hour for 23 hours. Comupted tomography (CT) head will be
      done at 24 hours in order to follow hematoma size. Electrocardiogram, lower extremity venous
      Doppler and NIHSS will also be done at 24 hours. The patient will be followed in the clinic
      30-90 days post discharge for functional status.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was withdrawn from IRB review on 03/08/16
  </why_stopped>
  <start_date type="Anticipated">June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hematoma volume</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lower extermity deep vein thrombosis on venous duplex ultrasound</measure>
    <time_frame>24-48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evidence of cardiac ischemia on the electrocardiogram</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>National Insitutes of Health Stroke Scale score</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale score</measure>
    <time_frame>30 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Intracerebral Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ɛ-Aminocaproic Acid</intervention_name>
    <description>Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Amicar</other_name>
    <other_name>Aminocaproic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years

          2. Supratentorial ICH ≤ 30 mL in volume and seen on ≥ 2 slices on a 0.5 mm CT head

          3. IVH involving &lt; 50% of the ipsilateral lateral ventricle will be allowed

          4. Treatment initiated within 1 hour of baseline CT and 3 hours of onset or last known
             normal

        Exclusion Criteria:

          1. Baseline mRS ≥ 2

          2. Infratentorial hemorrhage (brainstem/cerebellum)

          3. Any supratentorial hemorrhage extending to the brainstem

          4. ICH &gt; 30 mL

          5. Patients who undergo surgical evacuation

          6. Presenting outside of the 3 hour window

          7. Intraventricular extension &gt; 1/2 of one lateral ventricle

          8. Intraventricular extension into the 3rd or 4th ventricle, or the aqueduct or involving
             &gt;50% of the ipsilateral lateral ventricle

          9. ICH due to trauma

         10. ICH due to aneurysm of arteriovenous malformation

         11. ICH due to underlying neoplasm or infectious mass

         12. ICH due to Warfarin or other oral or intravenous anticoagulants

         13. International normalization ratio &gt; 1.4

         14. Life expectancy &lt; 1 year (prior to ICH onset); due to any cause.

         15. History of recent ischemic stroke (within the past 3 months)

         16. History of deep vein thrombosis or pulmonary embolism

         17. History of recent myocardial infarction (within the past 3 months)

         18. Known history of hypercoagulable state

         19. History of cancer

         20. Glomerular filtration rate &lt; 60 mL/min

         21. Received any hemostatic therapy for any indication (last 14 days)

         22. Received any investigational therapy in last 90 days

         23. &quot;Do Not Resuscitate&quot; order in place or expected, advance directives that could limit
             aggressive treatment measures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Misra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Louis Caron, MD, FRCS(C)</last_name>
    <role>Study Director</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reza Behrouz, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>December 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2015</study_first_posted>
  <last_update_submitted>July 5, 2017</last_update_submitted>
  <last_update_submitted_qc>July 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intracerebral Hemorrhage</keyword>
  <keyword>Stroke</keyword>
  <keyword>Cerebrovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aminocaproic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

